Market Place
Sourcing Support
Jaguar Health Reports Full Approval at April 2026 Meeting
20 Apr 2026 //
PHARMIWEB
Jaguar Health Reports 2025 Financials
07 Apr 2026 //
PHARMIWEB
Napo Pharmaceuticals Co-Sponsoring Gastroenterology Conference
02 Apr 2026 //
PHARMIWEB
Jaguar Health To Present Updates At Life Sciences Investor Forum
11 Mar 2026 //
PHARMIWEB
Jaguar Health Secures $3M Payment From Future Pak For Mytesi
03 Mar 2026 //
PHARMIWEB
Jaguar Health Sets Record Date For Special Stock Dividend
02 Mar 2026 //
PHARMIWEB
Jaguar Health Announces A Special One-Time Stock Dividend
18 Feb 2026 //
PHARMIWEB
Jaguar Inks $38M U.S. Crofelemer License Deal With Future Pak
12 Jan 2026 //
PHARMIWEB
Jaguar Health`s Crofelemer Study Shows Promising Results
06 Jan 2026 //
PHARMIWEB
Jaguar Health Receives $240K FDA Grant For Canalevia-CA1
02 Jan 2026 //
PHARMIWEB
FDA Renews Canalevia-CA1 Approval for Chemo Diarrhea
10 Dec 2025 //
PHARMIWEB
Jaguar Health Reports 4% Revenue Growth In Q3 2025
17 Nov 2025 //
PHARMIWEB
Jaguar Health Hosts Investor Webcast On Q3 2025 Financials Result
14 Nov 2025 //
PHARMIWEB
Jaguar Health Provides Recap of November 8, 2025 Presentation
13 Nov 2025 //
PHARMIWEB
Jaguar Health Unveils Crofelemer for Pediatric Intestinal Failure
06 Nov 2025 //
PHARMIWEB
Jaguar Health Introduces Employee Grants Per Nasdaq LR 5635(C)(4)
24 Oct 2025 //
PHARMIWEB
Jaguar Health Gets $250k FDA Grant For Canalevia Trial In Dogs
25 Sep 2025 //
PHARMAWEB
Jaguar Health to Present Updates at H.C. Wainwright Conference
05 Sep 2025 //
PHARMAWEB
Jaguar`s Proposals Approved at 2025 Annual Stockholders Meeting
19 Aug 2025 //
PHARMAWEB
Jaguar Health`s Investor Webcast on Q2 2025 Financials, Aug 14
12 Aug 2025 //
PHARMAWEB
Jaguar Health to Present at Emerging Growth Conference on June 18
17 Jun 2025 //
ACCESSWIRE
Jaguar Health Fireside Chat on Orphan Disease Development June 10
06 Jun 2025 //
ACCESSWIRE
Jaguar Health Announces $1.5M Direct Offering Under Nasdaq Rules
21 May 2025 //
ACCESSWIRE
Jaguar Health Investor Webcast on Q1 2025 Financials & Updates
14 May 2025 //
ACCESSWIRE
Jaguar Health Provides Overview of Crofelemer-Related Catalysts
07 May 2025 //
ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants
04 Apr 2025 //
ACCESSWIRE
Jaguar Health Closes Bridge Financing Under Nasdaq Rules
01 Apr 2025 //
ACCESSWIRE
Jaguar Health Meets FDA on Phase 3 OnTarget Study Results
27 Mar 2025 //
ACCESSWIRE
Jaguar Health to Present at Conference and Hold Webcast on Q4 2024
26 Mar 2025 //
ACCESSWIRE
Jaguar Health Announces Reverse Stock Split
18 Mar 2025 //
ACCESSWIRE
Jaguar Adopts Stockholder Rights Plan To Protect Long-Term Value
27 Feb 2025 //
ACCESSWIRE
Jaguar Extends NP-300 Deal For Cholera, Tropical Disease PRV
18 Feb 2025 //
ACCESSWIRE
Jaguar Health to Present at Emerging Growth Conference on Feb 18
13 Feb 2025 //
ACCESSWIRE
Magdalena Biosciences to Present at BIO CEO & Investor Conference
06 Feb 2025 //
ACCESSWIRE
Jaguar Health Doses 1st Patient in Short Bowel Syndrome Trial
03 Feb 2025 //
ACCESSWIRE
Jaguar Health Backs Crofelemer For GLP-1 GI Side Effects
29 Jan 2025 //
ACCESSWIRE
Jaguar`s New Employee Inducement Grants Under Nasdaq LR 5635(c)(4)
10 Jan 2025 //
ACCESSWIRE
Jaguar Announces Coca Leaf Import from Peru for Research
19 Dec 2024 //
ACCESSWIRE
Phase 2 Study Evaluates Jaguar’s Crofelemer for MVID
18 Dec 2024 //
ACCESSWIRE
Jaguar’s Crofelemer Show Positive Results For CTD In Breast Cancer
12 Dec 2024 //
ACCESSWIRE
Crofelemer for Cancer Therapy-Related Diarrhea Presented at SABCS
09 Dec 2024 //
ACCESSWIRE
Trial Begins For Crofelemer In Short Bowel Syndrome With IF
06 Dec 2024 //
ACCESSWIRE
Jaguar Health’s Canalevia-CA1 Approved for Chemo-Induced Diarrhea
05 Dec 2024 //
ACCESSWIRE
Jaguar Health Participates in Pet Connect Conference for NP300
02 Dec 2024 //
ACCESSWIRE
Jaguar Health to Present at NobleCon20 and Growth Conference
25 Nov 2024 //
ACCESSWIRE
Jaguar Seeks Partner for NP300 Antisecretory Drug for Dog Diarrhea
22 Nov 2024 //
ACCESSWIRE
Jaguar Health Reports Third Quarter 2024 Financial Results
13 Nov 2024 //
ACCESSWIRE
Jaguar Health to Hold Q3 2024 Financial Webcast on Nov 13
11 Nov 2024 //
ACCESSWIRE
FDA Approves Canalevia for Chemotherapy-Induced Diarrhea in Dogs
06 Nov 2024 //
ACCESSWIRE
Jaguar`s Crofelemer Shows Positive IBS-D Results at ACG Meeting
29 Oct 2024 //
ACCESSWIRE
Jaguar Health Launches FDA-Approved Gelclair In The U.S.
16 Oct 2024 //
ACCESSWIRE
Jaguar Announces Inducement Grants Under Nasdaq Rule
11 Oct 2024 //
ACCESSWIRE
Magdalena Biosciences To Present At BIO Investor Forum Oct 16
10 Oct 2024 //
ACCESSWIRE
Jaguar Health Submits Abstract For Cancer Diarrhea Study
08 Oct 2024 //
ACCESSWIRE
Jaguar Health Reports Positive Phase 3 Results For Crofelemer
01 Oct 2024 //
ACCESSWIRE
Jaguar Health To Present At MedInvest Conference
16 Sep 2024 //
ACCESSWIRE
Jaguar Health Appoints Veteran To Lead Oncology, HIV Sales
10 Sep 2024 //
ACCESSWIRE
Jaguar Health To Present At H.C. Wainwright Conference
06 Sep 2024 //
ACCESSWIRE
Jaguar Health Gets New Hong Kong Patent For Short Bowel Syndrome Treatment
19 Aug 2024 //
ACCESSWIRE
Jaguar Health To Hold Investor Webcast On Q2 Earnings And Trial Results
12 Aug 2024 //
ACCESSWIRE
